CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Traws Pharma, Inc. (TRAW) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Traws Pharma, Inc. (TRAW)

Pharmaceutical Preparations · market cap $7M · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
8
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Traws Pharma (TRAW) is a six-employee, roughly $5M market-cap pharma company with a multi-asset clinical pipeline: rigosertib-family assets (ON 01910.Na, oral rigosertib, rigosertib sodium) in MDS and head and neck squamous cell carcinoma, narazaciclib in endometrioid endometrial cancer, and ratutrelvir and TRX-100 in COVID-19 and influenza. Our data shows $5.0M of cash against a 2-month runway, and the equity trades at about $0.34. The setup is a balance-sheet story first and a clinical story second.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
Oral rigosertibPhase 2Myelodysplastic Syndromes
Ratutrelvir (83-0060) non-randomisedPhase 2COVID - 19
rigosertibPhase 2Head and Neck Squamous Cell Carcinoma
NarazaciclibPhase 2Endometrioid Endometrial Cancer
rigosertib sodiumPhase 3Myelodysplastic Syndromes
ON 01910.NaPhase 3Myelodysplastic Syndrome
TRX-100Phase 2Influenza
Ratutrelvir (83-0060)Phase 2COVID - 19
Price & technical context
3-month
-53.7%
6-month
-86.7%
12-month
-88.3%
52-wk range
$0.22–$2.82
vs 50-day MA
-41.6%
vs 200-day MA
-76.4%
Realized vol
133.0%
Max drawdown
-98.4%

Daily closes through 2026-11-13. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for TRAW (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.